Alembic Pharma

Who are in the management team of Alembic Pharma?

As of March 2023, the management team of Alembic Pharma includes Chirayu R Amin (Chairman & CEO), Pranav Amin and Shaunak Amin (Managing Directors), Rajkumar Baheti (CFO), and Manisha Saraf (Company Secretary), along with several independent directors. They oversee the company's strategic direction and operations.

As of March 2023, the management team of Alembic Pharma includes the following individuals:<BR><BR>1. Chirayu R Amin - Chairman & CEO<BR>2. Pranav Amin - Managing Director<BR>3. Shaunak Amin - Managing Director<BR>4. Rajkumar Baheti - Director (Finance) & CFO<BR>5. Manisha Saraf - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- Pranav N Parikh<BR>- K G Ramanathan<BR>- Paresh Saraiya<BR>- Archana Hingorani<BR>- Ashok Barat<BR>- Jai S Diwanji<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Has Alembic Pharma declared dividend?

Yes, Alembic Pharmaceuticals Ltd. has declared a 550% dividend, amounting to ₹11 per share, with an ex-date of July 15, 2024. While recent performance shows mixed returns, the company has demonstrated positive total returns over the 2-year (81.26%) and 5-year (20.15%) periods.

Alembic Pharmaceuticals Ltd. has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 11<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 1.13%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.25%, with no dividend return, resulting in a total return of -9.25%.<BR><BR>Over the past year, the price return was 10.07%, with a dividend return of 1.23%, leading to a total return of 11.3%.<BR><BR>In the 2-year period, the price return was 78.15%, with a dividend return of 3.11%, culminating in a total return of 81.26%.<BR><BR>For the 3-year period, the price return was 34.58%, with a dividend return of 4.03%, resulting in a total return of 38.61%.<BR><BR>In the last 4 years, the price return was 3.58%, with a dividend return of 4.30%, giving a total return of 7.88%.<BR><BR>Over the past 5 years, the price return was 15.37%, with a dividend return of 4.78%, leading to a total return of 20.15%.<BR><BR>Overall, Alembic Pharmaceuticals has declared a significant dividend, and while the recent performance shows mixed returns, the longer-term total returns indicate a positive trend, particularly over the 2-year and 5-year periods.

Who are the peers of the Alembic Pharma?

Alembic Pharma's peers include J B Chemicals, Pfizer, ERIS Lifescience, AstraZeneca, OneSource Specialty, Concord Biotech, Neuland Labs, Jubilant Pharma, Natco Pharma, and Sai Life. Management risk varies from excellent at Concord Biotech to average at Jubilant Pharma and Sai Life, with ERIS Lifescience showing the highest 1-year return at 74.62% and Natco Pharma the lowest at -20.35%.

Peers: The peers of Alembic Pharma are J B Chemicals &, Pfizer, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Concord Biotech, Neuland Labs., Jubilant Pharmo, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at J B Chemicals &, Pfizer, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Alembic Pharma, Neuland Labs., Natco Pharma, and the rest. Average management risk is noted at Jubilant Pharmo and Sai Life. Growth is Excellent at OneSource Speci., Good at Concord Biotech and Natco Pharma, Average at J B Chemicals & and Neuland Labs., and Below Average at Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, and the rest. Capital Structure is Excellent at J B Chemicals &, Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, Concord Biotech, Neuland Labs., and Natco Pharma, while Average is seen at Jubilant Pharmo and Below Average at OneSource Speci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ERIS Lifescience at 74.62%, while the lowest is Natco Pharma at -20.35%. Alembic Pharma's own 1-year return is -5.38%, which is higher than Natco Pharma's but lower than the rest. Additionally, Concord Biotech and Natco Pharma have negative six-month returns.

What does Alembic Pharma do?

Alembic Pharmaceuticals Ltd. is a large-cap company that manufactures and markets generic pharmaceutical products, primarily focusing on branded generics in India. As of March 2025, it reported net sales of ₹17,696 Cr and a net profit of ₹1,569 Cr.

Overview:<BR>Alembic Pharmaceuticals Ltd. manufactures and markets generic pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry as a large-cap company.<BR><BR>History:<BR>Incorporated on June 16, 2010, as a wholly owned subsidiary of Alembic Ltd., Alembic Pharmaceuticals has established itself as a leader in branded generics in India. The latest reported quarterly results indicate net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 17,696 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,569 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 20,257 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.07% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 11.03% <BR>Price to Book: 3.91<BR><BR>Contact Details:<BR>Address: Alembic Road, Vadodara Gujarat : 390003 <BR>Tel: 91-0265-2280550 <BR>Email: apl.investors@alembic.co.in <BR>Website: http://www.alembicpharmaceuticals.com

Who are the top shareholders of the Alembic Pharma?

The top shareholders of Alembic Pharma include Nirayu Limited with 35.64%, mutual funds holding 9.2%, foreign institutional investors at 3.94%, and DSP Midcap Fund as the largest public shareholder with 4.6%. Individual investors own 7.07% of the total shares.

The top shareholders of Alembic Pharma include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nirayu Limited, which owns 35.64% of the company. Additionally, mutual funds collectively hold 9.2% through 21 different schemes, while foreign institutional investors (FIIs) account for 3.94% with 151 FIIs involved. The highest public shareholder is DSP Midcap Fund, holding 4.6%. Individual investors also have a stake, representing 7.07% of the total shares.

How big is Alembic Pharma?

As of 24th July, Alembic Pharmaceuticals Ltd. has a market capitalization of 20,115.00 Cr, with net sales of 6,672.09 Cr and a net profit of 583.43 Cr reported in the latest four quarters. The company has shareholder's funds of 5,190.94 Cr and total assets of 7,606.90 Cr for the annual period ending in March 2025.

As of 24th July, Alembic Pharmaceuticals Ltd. has a market capitalization of 20,115.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Alembic Pharmaceuticals reported net sales of 6,672.09 Cr and a net profit of 583.43 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has shareholder's funds amounting to 5,190.94 Cr and total assets of 7,606.90 Cr.

When is the next results date for Alembic Pharma?

The next results date for Alembic Pharma is 04 November 2025.

The next results date for Alembic Pharma is scheduled for 04 November 2025.

Is Alembic Pharma overvalued or undervalued?

As of November 6, 2025, Alembic Pharma is considered very attractive and undervalued compared to peers, with a PE ratio of 28.37 and a PEG ratio of 0.00, indicating strong growth potential despite recent stock performance declines.

As of 6 November 2025, Alembic Pharma's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its valuation outlook. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 28.37, an EV to EBITDA of 27.19, and a Price to Book Value of 0.34, which highlight its potential for growth relative to its market price.<BR><BR>In comparison to its peers, Alembic Pharma's valuation stands out; for instance, Sun Pharma has a PE ratio of 35.02 and Divi's Lab is at 79.09, both categorizing them as expensive. Additionally, while Alembic Pharma's PEG ratio is 0.00, indicating no growth premium, competitors like Cipla and Dr. Reddy's Labs have PEG ratios of 1.25 and 2.15, respectively, suggesting that Alembic may offer better value. Despite a recent decline in stock performance relative to the Sensex over the past year, the company's strong fundamentals and attractive valuation metrics position it favorably in the market.

How has been the historical performance of Alembic Pharma?

Alembic Pharma has shown consistent growth in net sales, reaching 6,672.08 Cr in March 2025, but profit after tax declined to 581.14 Cr. Total assets increased to 7,606.90 Cr, while cash flow from operating activities significantly dropped to 87.00 Cr, indicating potential cash management challenges.

Answer:<BR>The historical performance of Alembic Pharma shows a trend of increasing net sales and total operating income over the years, with net sales reaching 6,672.08 Cr in March 2025, up from 6,228.63 Cr in March 2024 and 5,652.62 Cr in March 2023. The total expenditure has also risen, amounting to 5,663.84 Cr in March 2025, compared to 5,295.27 Cr in March 2024. Operating profit, excluding other income, was 1,008.24 Cr in March 2025, reflecting a steady increase from 933.36 Cr in March 2024. However, profit after tax showed a slight decline to 581.14 Cr in March 2025 from 616.80 Cr in March 2024. The company's total assets increased to 7,606.90 Cr in March 2025, up from 6,275.94 Cr in March 2024, while total liabilities also rose to 7,606.90 Cr in March 2025, compared to 6,275.94 Cr in March 2024. Cash flow from operating activities decreased significantly to 87.00 Cr in March 2025 from 803.00 Cr in March 2024, indicating a shift in cash generation capabilities.<BR><BR>Breakdown:<BR>Alembic Pharma's financial performance has demonstrated a consistent growth trajectory in net sales, which increased from 5,305.79 Cr in March 2022 to 6,672.08 Cr in March 2025. This growth in sales has been accompanied by rising total operating income, which reached 6,672.08 Cr in March 2025. Despite this increase, the total expenditure also rose, leading to an operating profit of 1,008.24 Cr in March 2025, an improvement from the previous year. However, profit after tax saw a decrease to 581.14 Cr in March 2025, down from 616.80 Cr in March 2024. The company's total assets grew significantly to 7,606.90 Cr in March 2025, reflecting a robust asset base, while total liabilities increased correspondingly. The cash flow from operating activities, however, faced a notable decline, indicating potential challenges in cash management despite the overall growth in sales and assets.

Is Alembic Pharma technically bullish or bearish?

As of December 1, 2025, Alembic Pharma's technical outlook is bearish, driven by negative indicators such as a bearish MACD, moving averages, and KST, with no signs of bullish momentum from the RSI.

As of 1 December 2025, the technical trend for Alembic Pharma has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Both Bollinger Bands and the monthly MACD are mildly bearish, indicating a continuation of negative momentum. The RSI shows no signals on both weekly and monthly time frames, suggesting a lack of bullish momentum. Overall, the technical outlook remains negative.

Are Alembic Pharmaceuticals Ltd. latest results good or bad?

Alembic Pharmaceuticals Ltd.'s latest Q3 FY26 results are considered bad, with a 28.01% drop in net profit quarter-on-quarter and a decline in profit margins, despite a 10.84% year-on-year sales growth. The company's operational challenges have led to a downgrade in its quality grade and bearish investor sentiment.

Alembic Pharmaceuticals Ltd.'s latest results for Q3 FY26 indicate a challenging period for the company. While the net sales showed a year-on-year growth of 10.84%, there was a sequential decline of 1.77% compared to the previous quarter. This suggests that although the company is generating more revenue compared to last year, it is struggling to maintain its momentum on a quarter-to-quarter basis.<BR><BR>The net profit has seen a significant drop, falling by 28.01% quarter-on-quarter and 3.94% year-on-year, which raises concerns about the company's operational efficiency. The profit after tax (PAT) margin also compressed sharply from 9.62% in the previous quarter to just 7.03%, indicating rising costs and potential issues with pricing power.<BR><BR>Overall, the results reflect operational challenges and a deteriorating financial performance, leading to a downgrade in the company's quality grade from "Excellent" to "Average." The stock has underperformed significantly, trading well below its 52-week high, and investor sentiment appears to be bearish. Given these factors, the latest results can be characterized as bad, highlighting the need for the company to address its operational issues to regain investor confidence.

Should I buy, sell or hold Alembic Pharmaceuticals Ltd.?

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 17-Mar, Alembic Pharmaceuticals Ltd. is facing a significant decline in its stock price, currently at Rs. 665.10, down 1.26%. The stock has underperformed over various periods, hitting a new 52-week low and showing decreased investor confidence.

As of 17-Mar, Alembic Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs. 665.10, which reflects a change of -8.5 (-1.26%). This drop is part of a broader trend, as the stock has been underperforming significantly over various periods. Over the past week, it has fallen by -6.62%, and in the last month, the decline is even steeper at -14.34%. Year-to-date, the stock has decreased by -21.59%, contrasting sharply with the Sensex, which has only fallen by -10.74% during the same timeframe.<BR><BR>Today's performance is particularly notable as the stock has hit a new 52-week low, indicating a significant downturn. It has underperformed its sector by -1.54% today and has been on a consecutive decline for the last five days. Additionally, the stock is trading below its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals weakness in price momentum.<BR><BR>Investor participation appears to be waning, with a delivery volume of 22.47k on March 16, which is down by -18.4% compared to the 5-day average delivery volume. This decline in trading activity suggests a lack of confidence among investors, further contributing to the stock's falling price. Overall, these factors collectively indicate that Alembic Pharmaceuticals Ltd. is currently facing significant challenges, leading to its declining stock price.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 18-Mar, Alembic Pharmaceuticals Ltd. is seeing a short-term stock price increase to 675.75, following five days of decline, but it has a year-to-date drop of 20.33% and is near its 52-week low. Despite the recent rise, long-term performance remains weak, with decreased investor interest and a bearish trend indicated by trading below moving averages.

As of 18-Mar, Alembic Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 675.75, which reflects an increase of 5.25 (0.78%). This upward movement comes after a period of five consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 0.51% today, suggesting a relative strength compared to its peers.<BR><BR>Despite this short-term rise, the stock has faced significant challenges over a longer timeframe. It has seen a decline of 20.33% year-to-date and a 19.05% drop over the past year. The stock is also trading close to its 52-week low, just 1.58% away from Rs 665.1. Furthermore, it is trading below its moving averages across various timeframes, indicating a bearish trend in the longer term.<BR><BR>Investor participation has decreased, with a delivery volume that has fallen by 19.48% against the 5-day average, which may reflect waning interest among investors. However, the company does have some positive attributes, such as a strong ability to service debt, a low Debt to EBITDA ratio of 0.90 times, and a high institutional holding at 20.41%, which could provide some support for the stock.<BR><BR>In summary, while Alembic Pharmaceuticals Ltd. is currently rising in price, this is set against a backdrop of poor long-term growth and significant declines in recent performance metrics.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 19-Mar, Alembic Pharmaceuticals Ltd. is facing a significant decline in stock price, currently at 663.50, with a year-to-date drop of 21.78%. The stock is underperforming against the broader market and trading below all moving averages, indicating a bearish trend.

As of 19-Mar, Alembic Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 663.50, which reflects a change of -12.25 (-1.81%). The stock has hit a new 52-week low of Rs. 653 today, indicating significant downward pressure. Over the past week, the stock has decreased by 5.41%, and it has shown a substantial decline of 21.78% year-to-date, which is notably worse than the Sensex's decline of 12.92% during the same period.<BR><BR>The stock's performance has been consistently poor, with a 1-month decline of 13.51% and a 1-year decline of 21.19%. This underperformance is compounded by the fact that the stock is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend.<BR><BR>Additionally, the company has faced challenges such as a negative annual growth rate of operating profit at -8.78% over the last five years, and its inventory turnover ratio is at its lowest, suggesting inefficiencies. Despite a rise in profits by 11.7% over the past year, the stock's overall return remains negative, leading to a PEG ratio of 1.7, which indicates that the stock may not be a favorable investment at this time.<BR><BR>The broader sector, Pharmaceuticals & Drugs, has also seen a decline of 2.13%, contributing to the negative sentiment surrounding Alembic Pharmaceuticals. Although there has been an increase in investor participation, with delivery volume rising by 10.77% against the 5-day average, the overall indicators suggest that the stock is facing significant challenges, leading to its current downward trajectory.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 20-Mar, Alembic Pharmaceuticals Ltd. is seeing a stock price increase to 680.15, up 3.64%, driven by positive market sentiment and strong investor participation. Despite a year-over-year decline of 18.38%, the company's financial metrics suggest it may be undervalued, supported by high institutional holdings.

As of 20-Mar, Alembic Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 680.15, reflecting an increase of 23.9 or 3.64%. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 1.94% today, indicating positive market sentiment. Additionally, the stock reached an intraday high of Rs 685.4, which is a 4.44% increase, suggesting strong buying interest.<BR><BR>Investor participation has also increased, with a delivery volume of 29.72k on March 19, which is up by 35.87% compared to the 5-day average. This rise in trading volume indicates that more investors are willing to hold the stock, which typically supports price increases. Furthermore, the company demonstrates a strong ability to service its debt, evidenced by a low Debt to EBITDA ratio of 0.90 times, and it has an attractive valuation with a return on capital employed (ROCE) of 12.6.<BR><BR>Despite the stock's recent performance, which has seen a decline of 18.38% over the past year, the company's profits have increased by 11.7%, leading to a PEG ratio of 1.7. This suggests that the stock may be undervalued compared to its earnings growth potential. Additionally, high institutional holdings at 20.41% indicate confidence from larger investors who typically have more resources to analyze the company's fundamentals.<BR><BR>Overall, the combination of positive trading activity, strong financial metrics, and institutional support contributes to the rising stock price of Alembic Pharmaceuticals Ltd.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 23-Mar, Alembic Pharmaceuticals Ltd. is facing a significant decline in its stock price, currently at 649.35, with a new 52-week low of Rs. 635.3. The stock has underperformed the sector and shows a year-to-date drop of -23.44%, reflecting a bleak outlook due to poor long-term growth and negative sentiment in the pharmaceuticals sector.

As of 23-Mar, Alembic Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 649.35, which reflects a change of -27.7 or -4.09%. The stock has hit a new 52-week low of Rs. 635.3 today, indicating significant downward pressure. This decline is further evidenced by the stock's performance, which has underperformed the sector by -0.52% and has touched an intraday low of Rs. 635.3, representing a drop of -6.17%.<BR><BR>Over the past week, the stock has decreased by -3.60%, and its performance over the last month shows a substantial decline of -15.76%. Year-to-date, the stock has fallen by -23.44%, and over the past year, it has generated a return of -31.49%. This poor performance is compounded by the fact that Alembic Pharmaceuticals is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.<BR><BR>Additionally, the broader pharmaceuticals and drugs sector has also seen a decline of -3.62%, contributing to the negative sentiment surrounding the stock. Despite some positive factors, such as a strong ability to service debt and rising investor participation, the overall outlook remains bleak due to poor long-term growth, as evidenced by an annual operating profit decline of -8.78% over the last five years and below-par performance in both the near and long term.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 24-Mar, Alembic Pharmaceuticals Ltd. is seeing a stock price increase to 673.60, up 4.23%, driven by strong trading momentum and heightened investor interest, evidenced by a significant rise in delivery volume. Despite a poor long-term growth record, improving fundamentals and strong institutional holdings suggest a potential shift in investor sentiment.

As of 24-Mar, Alembic Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 673.60, reflecting an increase of 27.35 or 4.23%. This upward movement can be attributed to several factors. Firstly, the stock outperformed its sector by 3.11% today and opened with a gain of 2.01%. It also reached an intraday high of Rs 677, indicating positive trading momentum.<BR><BR>Additionally, there has been a significant increase in investor participation, with delivery volume rising by 192.91% against the 5-day average, suggesting heightened interest from investors. The company's strong ability to service debt, evidenced by a low Debt to EBITDA ratio of 0.90 times, and an attractive valuation with a Return on Capital Employed (ROCE) of 12.6 further support the stock's positive performance. <BR><BR>Despite the stock's poor long-term growth and negative returns over the past year, where it generated -30.07%, the recent rise in price indicates a potential shift in investor sentiment, possibly driven by the company's improving fundamentals and strong institutional holdings at 20.41%. Overall, the combination of positive trading activity and strong financial metrics appears to be contributing to the stock's current rise.

Why is Alembic Pharmaceuticals Ltd. falling/rising?

As of 25-Mar, Alembic Pharmaceuticals Ltd. has seen its stock price rise to Rs 692.45, up 2.9%, driven by strong investor interest and a significant increase in delivery volume. Despite a 25.96% decline over the past year, recent gains suggest a potential shift in market sentiment.

As of 25-Mar, Alembic Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at Rs 692.45, which reflects an increase of Rs 19.5 or 2.9%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.01% today and has shown a consecutive gain over the last two days, accumulating a total return of 7.15% during this period. Additionally, the stock reached an intraday high of Rs 698.25, indicating strong buying interest.<BR><BR>Investor participation has also increased, with a delivery volume of 1.12 lacs on 24 March, which is a significant rise of 196.93% compared to the 5-day average. This heightened activity suggests growing confidence among investors. Furthermore, the company's strong ability to service debt, evidenced by a low Debt to EBITDA ratio of 0.90 times, along with a favorable Return on Capital Employed (ROCE) of 12.6, contributes to its attractive valuation. The stock is trading at a discount relative to its peers, which may further entice investors.<BR><BR>Despite the positive short-term performance, it is important to note that the stock has faced challenges over the longer term, including a decline of 25.96% in the past year. However, the recent gains and improved investor sentiment indicate a potential shift in market perception, at least in the short term.

Which are the latest news on Alembic Pharma?